Key Highlights
- MindBio Therapeutics says product testing reached up to 83% intoxication-detection accuracy under certain conditions.
- The company plans further human testing over the next 2 03 weeks before a first commercial pilot.
- MindBio plans a non-brokered private placement of up to CAD$350,000 and a CAD$38,000 debt conversion.
MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) said it is nearing final product testing for its first commercial pilot of an artificial-intelligence voice analytics system designed to detect drug and alcohol intoxication, and that it is reporting up to 83% accuracy under certain testing conditions.
The company said its prediction models, with and without sober baseline tracking, are now exceeding the accuracy of some commonly used commercially available cheek swab tests. It also said it plans further human testing over the next 2 03 weeks before launching its first commercial pilot product.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
MindBio previously announced on Oct. 14, 2026, that it had completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk. The company said it has spent the past six months refining its proprietary intoxication prediction models, with a focus on improving predictive accuracy, reliability and robustness.
MindBio expects to launch what it described as the first commercially ready iteration of the product in Spanish, combining its voice-based software and purpose-built hardware into an integrated system intended for commercial deployment.
Financing and debt conversion
MindBio said it will conduct a non-brokered private placement of up to 3,888,889 units at $0.09 per unit for gross proceeds of up to CAD$350,000. Each unit is to include one common share and one-half of one common share purchase warrant, with each whole warrant exercisable at $0.16 per share for 36 months after the offerings closing date.
The company said it intends to use the proceeds for general working capital and to fund its annual audit and legal expenses, as well as OTC and Canadian Securities Exchange listing expenses.
Separately, MindBio said it has agreed to convert CAD$38,000 of debt owed to an arms-length lender into units at $0.09 per unit, for a total of 422,222 units.
MindBio said securities issued under the private placement and debt conversion will be subject to a four-month-and-one-day resale restriction under applicable securities laws, and that completion of both transactions remains subject to regulatory approvals.
The original press release is available on stockhouse.com
s-13v4_h-14v4_i-15v4